A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects With Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2018
At a glance
- Drugs AMG-424 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 13 Aug 2018 Planned End Date changed from 4 Nov 2020 to 8 Jul 2021.
- 13 Aug 2018 Planned primary completion date changed from 4 Nov 2020 to 8 Jul 2021.
- 13 Aug 2018 Status changed from not yet recruiting to recruiting.